Characterization of Histaminergic Receptors

互联网2013-12-31

1979

Abstract
Table of Contents
Materials
Figures
Literature Cited

Abstract

This unit describes radioligand binding protocols for histamine H₁ , H₂ , H₃ , and H₄ receptors. Because these receptors demonstrate low amino acid sequence homology and divergent pharmacological characteristics, assay conditions vary for each. These protocols can be employed in high?throughput screening programs aimed at identifying selective agonists and antagonists for these sites.

Keywords: histaminergic receptors; H1 histamine receptors; H2 histamine receptors; H3 histamine receptors; H4 histamine receptors; radioligand binding assays; antihistamines

GO TO THE FULL PROTOCOL:

PDF or HTML at Wiley Online Library

Strategic Planning
Basic Protocol 1: Measurement of [3H]Mepyramine Binding to Cloned Human H1 Receptors
Alternate Protocol 1: Measurement of [3H]mepyramine Binding to Native H1 Receptors in Tissue Membrane Homogenates
Basic Protocol 2: Measurement Of [3H]tiotidine Binding to Cloned Human H2 Receptors
Alternate Protocol 2: Measurement of [125I]aminopotentidine Binding to Native H2 Receptors in Tissue Membrane Homogenates
Basic Protocol 3: Measurement of [3H]N‐α‐Methyl Histamine Binding to Cloned Human H3 Receptors in Membranes
Alternate Protocol 3: Measurement of [3H]N‐α‐Methyl Histamine Binding to Native H3 Receptors
Basic Protocol 4: Measurement of [3H]histamine Binding to Cloned Human H4 Receptors in Membranes
Support Protocol 1: Data Analysis
Reagents and Solutions
Commentary
Literature Cited
Figures
Tables

GO TO THE FULL PROTOCOL:

PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1: Measurement of [3H]Mepyramine Binding to Cloned Human H1 Receptors

Materials

Cell line (e.g., HEK‐293 cells; ATCC# CRL‐1573) stably transfected (see De Backer et al., ) with human H₁ receptors using Lipofectamine 2000 (Life Technologies), grown to confluence
Cell dissociation buffer (Life Technologies), prewarmed to 37°C
Dulbecco's phosphate‐buffered saline (DPBS; calcium‐ and magnesium‐free; see recipe ), ice‐cold
Na⁺ /K⁺ assay buffer (see recipe ), 25°C
20 µM promethazine (Research Biochemicals) in 50 mM Na⁺ /K⁺ assay buffer (see recipe ), or other unlabeled ligand to measure nonspecific binding (Table 1.19.2 )
1.5 nM [³ H]mepyramine (20 to 30 Ci/mmol; Perkin‐Elmer Life Sciences; Table 1.19.3 ) in Na⁺ /K⁺ assay buffer (see recipe )
Test compounds (optional) in Na⁺ /K⁺ assay buffer (see recipe )
0.5% (v/v) polyethyleneimine (PEI)
Rinse buffers (50 mM Tris·Cl; appendix 2A ): pH 7.7 at 25°C, pH 7.4 at 0°C
Scintillation cocktail: e.g., Microscint 20 (Packard) or Ready‐Solv HP (Beckman Coulter)

Tissue homogenizer (e.g., T 25 Ultra‐Turrax; IKA Works)
Deep‐well 96‐well microtiter plates (2.2 ml volume; e.g., Bioblocks, Brandel), 2‐ml strip tubes, or 12×75–mm glass test tubes
GF/B Unifilter plates (Packard), or equivalent
Cell harvester or vacuum filtration manifold (e.g., Packard, Brandel, or Skatron), optional
60°C oven, optional

Additional reagents and equipment for performing Bradford, Lowry, or BCA protein assays ( appendix 3A )

Table 1.9.2 MaterialsAffinity Constants (K _i Values) of Reference Agents for the Cloned Human H₁ , H₂ , H₃ , and H₄ ReceptorsProperties of Commercially Available Radioligands for Histamine Receptors

Compound	K _i values (nM)	Compound source
	H₁	H₂	H₃	H₄
Agonists
Histamine	6500	33,000	7.0	8.1 d	Sigma
Imetit	30,000	39,000	0.40	2.7 d	RBI
Immepip	22,000	>100,000	2.8	9.0 d	Tocris Cookson
N ‐α‐methyl histamine	10,000	42,000	2.6	23 d	RBI
R ‐α‐methyl histamine	57,000	>100,000	2.1	146 d	RBI
S ‐α‐methyl histamine	>100,000	>100,000	38	–	RBI

H₁ Antagonists
Chlorpheniramine	7.6	6100	1500	–	RBI
Diphenhydramine	17	2500	>10,000	>10,000 d	RBI
Promethazine	5.0	200	>10,000	–	RBI

H₂ Antagonists
Burimamide	>100,000	2,600	5.1	180 d	Smith‐Kline Beecham c
Cimetidine	>10,000	320	>100,000	>10,000 d	RBI
Ranitidine	>10,000	77	21,000	>10,000 d	RBI
Tiotidine	>100,000	27	30,000	–	Tocris Cookson
Zolantidine	1200	41	1700	–	Tocris Cookson

H₃ Antagonists
Ciproxifan	45,000	80,000	0.75	1880	Bioprojet c
Clobenpropit	2900	5000	0.84	12.8 d	RBI
Iodophenpropit	800	1100	0.72	–	Tocris Cookson
Thioperamide	>100,000	>100,000	72.6	27 d	Tocris Cookson
A‐331440	2940	14,400	3.2	>10,000	Sigma
ABT‐239	1620	6760	0.45	>10,000	Abbott Labs c

H₄ Antagonists
Thioperamide	>100,000	>100,000	72.6	27 d	Tocris Cookson
JNJ7777140 c	>10,000 d	>1000 d	>5000 d	4.1 d	Johnson & Johnson
Radioligand	Agonist or antagonist	K _d for receptor (nM)	Specific activity (Ci/mmol)	Nonspecific binding	Signal‐to‐noise ratio	Source	Comments
H₁ Receptor
[³ H]Mepyramine	Antagonist	0.5 ‐ 2.0	20‐30	Low	High	Perkin‐Elmer

H₂ Receptor
[³ H]Cimetidine	Antagonist	100‐500	10‐30	High	Low	Amersham
[³ H]Tiotidine	Antagonist	2‐10	70‐90	High	Low	Perkin‐Elmer	Good SNR for recombinant receptors
[¹²⁵ I]Iodo‐aminopotentidine	Antagonist	0.1‐0.5	2000	High	Low	Amersham	Cost‐limiting for broad‐based screening Custom synthesis required

H₃ Receptor
[³ H]Histamine	Agonist	2‐10	25‐30	High	Low	Perkin‐Elmer	Selectivity: H₃ > H₄ > H₁ > H₂
[³ H]R ‐α‐methyl histamine	Agonist	0.2‐0.8	20‐50	Moderate	Moderate	Amersham
[³ H]N ‐α‐methyl histamine	Agonist	0.2‐0.8	45‐90	Low	High	Perkin‐Elmer	SNR in tissue‐based assays > RαMH
[¹²⁵ I]Iodo‐proxyfan	Antagonist	0.2‐0.5	2000	High	Low	Amersham	Binds to H₃ R and sites displaced by metyrapone

H₄ Receptor
[³ H]Histamine	Agonist	50‐200	25‐30	High	Low	Perkin‐Elmer	Selectivity: H₃ > H₄ > H₁ > H₂

^c Not available commercially.

^d Liu et al., .

Table 1.9.3 MaterialsAffinity Constants (K _i Values) of Reference Agents for the Cloned Human H₁ , H₂ , H₃ , and H₄ ReceptorsProperties of Commercially Available Radioligands for Histamine Receptors

Compound	K _i values (nM)	Compound source
	H₁	H₂	H₃	H₄
Agonists
Histamine	6500	33,000	7.0	8.1 d	Sigma
Imetit	30,000	39,000	0.40	2.7 d	RBI
Immepip	22,000	>100,000	2.8	9.0 d	Tocris Cookson
N ‐α‐methyl histamine	10,000	42,000	2.6	23 d	RBI
R ‐α‐methyl histamine	57,000	>100,000	2.1	146 d	RBI
S ‐α‐methyl histamine	>100,000	>100,000	38	–	RBI

H₁ Antagonists
Chlorpheniramine	7.6	6100	1500	–	RBI
Diphenhydramine	17	2500	>10,000	>10,000 d	RBI
Promethazine	5.0	200	>10,000	–	RBI

H₂ Antagonists
Burimamide	>100,000	2,600	5.1	180 d	Smith‐Kline Beecham c
Cimetidine	>10,000	320	>100,000	>10,000 d	RBI
Ranitidine	>10,000	77	21,000	>10,000 d	RBI
Tiotidine	>100,000	27	30,000	–	Tocris Cookson
Zolantidine	1200	41	1700	–	Tocris Cookson

H₃ Antagonists
Ciproxifan	45,000	80,000	0.75	1880	Bioprojet c
Clobenpropit	2900	5000	0.84	12.8 d	RBI
Iodophenpropit	800	1100	0.72	–	Tocris Cookson
Thioperamide	>100,000	>100,000	72.6	27 d	Tocris Cookson
A‐331440	2940	14,400	3.2	>10,000	Sigma
ABT‐239	1620	6760	0.45	>10,000	Abbott Labs c

H₄ Antagonists
Thioperamide	>100,000	>100,000	72.6	27 d	Tocris Cookson
JNJ7777140 c	>10,000 d	>1000 d	>5000 d	4.1 d	Johnson & Johnson
Radioligand	Agonist or antagonist	K _d for receptor (nM)	Specific activity (Ci/mmol)	Nonspecific binding	Signal‐to‐noise ratio	Source	Comments
H₁ Receptor
[³ H]Mepyramine	Antagonist	0.5 ‐ 2.0	20‐30	Low	High	Perkin‐Elmer

H₂ Receptor
[³ H]Cimetidine	Antagonist	100‐500	10‐30	High	Low	Amersham
[³ H]Tiotidine	Antagonist	2‐10	70‐90	High	Low	Perkin‐Elmer	Good SNR for recombinant receptors
[¹²⁵ I]Iodo‐aminopotentidine	Antagonist	0.1‐0.5	2000	High	Low	Amersham	Cost‐limiting for broad‐based screening Custom synthesis required

H₃ Receptor
[³ H]Histamine	Agonist	2‐10	25‐30	High	Low	Perkin‐Elmer	Selectivity: H₃ > H₄ > H₁ > H₂
[³ H]R ‐α‐methyl histamine	Agonist	0.2‐0.8	20‐50	Moderate	Moderate	Amersham
[³ H]N ‐α‐methyl histamine	Agonist	0.2‐0.8	45‐90	Low	High	Perkin‐Elmer	SNR in tissue‐based assays > RαMH
[¹²⁵ I]Iodo‐proxyfan	Antagonist	0.2‐0.5	2000	High	Low	Amersham	Binds to H₃ R and sites displaced by metyrapone

H₄ Receptor
[³ H]Histamine	Agonist	50‐200	25‐30	High	Low	Perkin‐Elmer	Selectivity: H₃ > H₄ > H₁ > H₂

Alternate Protocol 1: Measurement of [3H]mepyramine Binding to Native H1 Receptors in Tissue Membrane Homogenates

Male Hartley strain guinea pigs, 6 to 8 months in age
0.9% NaCl solution in squeeze bottle

Dissection instruments (e.g., Stoelting)
- Small animal decapitator
- Operating scissors
- Bone rongeurs
- Strong forceps
- Cold dissecting plate (or ice‐filled Petri dish)
- Scalpel
- Dissecting knife
Gas cylinder containing 60% CO₂ /40% O₂ connected to a suitable chamber for anesthetizing guinea pig

Basic Protocol 2: Measurement Of [3H]tiotidine Binding to Cloned Human H2 Receptors

Materials

Na⁺ /K⁺ assay buffer (see recipe ), ice‐cold
1 mM cimetidine (Research Biochemicals) in 50 mM Na⁺ /K⁺ assay buffer, or other unlabeled ligand to measure nonspecific binding (Table 1.19.2 )
0.75 nM [³ H]tiotidine (70 to 90 Ci/mmol; Perkin‐Elmer Life Sciences; Table 1.19.3 ) in 50 mM Na⁺ /K⁺ assay buffer (see recipe )
Test compounds (optional) in Na⁺ /K⁺ assay buffer (see recipe )
0.5% (v/v) polyethyleneimine (PEI)
Rinse buffer, ice‐cold: 50 mM Tris·Cl ( appendix 2A ), pH 7.7 at 25°C, pH 7.4 at 0°C
Scintillation fluid: Microscint 20 (Packard) or Ready‐Solv HP (Beckman Coulter)

Deep well 96‐well microtiter plates (2.2‐ml volume; e.g., Bioblocks, Brandel), 2‐ml strip tubes, or 12×75–mm glass test tubes
GF/B filters or Unifilter GF/B plates (Packard), or equivalent
Cell harvester or vacuum filtration manifold (e.g., Packard, Brandel, or Skatron), optional
60°C oven, optional

Additional reagents and equipment for preparing membranes (see protocol 1 ) and performing Bradford, Lowry, or BCA protein assays ( appendix 3A )

Alternate Protocol 2: Measurement of [125I]aminopotentidine Binding to Native H2 Receptors in Tissue Membrane Homogenates

Male Hartley strain guinea pigs, 6 to 8 months in age
0.9% NaCl solution in squeeze bottle
500 µM cimetidine (Research Biochemicals) in 50 mM Na⁺ /K⁺ assay buffer, or other unlabeled ligand to measure nonspecific binding (Table 1.19.2 )
60 pM [¹²⁵ I]iodoaminopotentidine (2000 Ci/mmol; Amersham; Table 1.19.3 ) in 50 mM Na⁺ /K⁺ assay buffer

Dissection instruments (e.g., Stoelting)
- Small animal decapitator
- Operating scissors
- Bone rongeurs
- Strong forceps
- Cold dissecting plate (or ice‐filled Petri dish)
- Scalpel
- Dissecting knife
Gas cylinder containing 60% CO₂ /40% O₂ connected to a suitable chamber for anesthetizing guinea pig

Additional reagents and equipment for preparing guinea pig cortical membranes ( protocol 2 )

Basic Protocol 3: Measurement of [3H]N‐α‐Methyl Histamine Binding to Cloned Human H3 Receptors in Membranes

Materials

Cell line (e.g., HEK‐293 cells, ATCC #CRL‐1573, or rat C6 glioma, ATCC #CCL‐107) transfected (see Lovenberg et al., ) with human H₃ receptors, grown to confluence
TEP assay buffer (see recipe )
Tris/EDTA assay buffer (without proteases; see recipe ), ice‐cold
100 µM histamine (Research Biochemicals) in Tris/EDTA assay buffer, or other unlabeled ligand (e.g., 30 µM thioperamide; Tocris Cookson) to measure nonspecific binding (Table 1.19.2 )
1 nM [³ H]N ‐α‐methyl histamine (NAMH; 45 to 90 Ci/mmol; Perkin‐Elmer Life Sciences; Table 1.19.3 ) in Tris/EDTA assay buffer (see recipe )
Test compounds (optional) in Tris/EDTA assay buffer (see recipe )
0.5% (v/v) polyethyleneimine (PEI)
Rinse buffer, ice‐cold: 50 mM Tris·Cl ( appendix 2A ), pH 7.7 at 25°C, pH 7.4 at 0°C
Scintillation fluid: Microscint 20 (Packard) or Ready‐Solv HP (Beckman Coulter)

Tissue homogenizer (e.g., T 25 Ultra‐Turrax; IKA Works)
Clinical tabletop centrifuge
Deep‐well 96‐well microtiter plates (2.2‐ml volume, e.g., Bioblocks, Brandel), 2‐ml strip tubes, or 12 × 75–mm glass test tubes
GF/B filters or Unifilter GF/B plates (Packard)
Cell harvester or vacuum filtration manifold (e.g., Packard, Brandel, or Skatron)
60°C oven (optional)

Additional reagents and equipment for preparing membranes (see protocol 1 and protocol 2 ) and for Bradford, Lowry, or BCA protein assays ( appendix 3A )

Alternate Protocol 3: Measurement of [3H]N‐α‐Methyl Histamine Binding to Native H3 Receptors

Male Sprague‐Dawley rat (200 to 250 g) or male Hartley guinea pig (6 to 8 months in age)
TEP assay buffer (see recipe ), ice‐cold
Tris‐EDTA assay buffer (see recipe )
30 µM thioperamide (Tocris Cookson) in TEP assay buffer, or other unlabeled ligand to measure nonspecific binding (Table 1.19.2 )
1.5 nM [³ H]N‐α‐methyl histamine (NAMH; 45 to 90 Ci/mmol; Perkin‐Elmer Life Sciences; Table 1.19.3 ) in TEP assay buffer

Additional reagents and equipment for obtaining brain tissue ( protocol 2 )

Basic Protocol 4: Measurement of [3H]histamine Binding to Cloned Human H4 Receptors in Membranes

Materials

Cell lines (e.g., human HEK‐293, ATCC# CRL‐1573; or SK‐N‐MC, ATCC# HTB‐10) transfected (Liu et al., ) with human H₄ receptors, grown to confluence
TEP assay buffer (see recipe )
Tris‐EDTA assay buffer (see recipe )
200 µM thioperamide (Tocris Cookson) in Tris‐EDTA assay buffer (see recipe ) to define nonspecific binding
[³ H]histamine (Perkin‐Elmer)
Test compounds
Scintillation cocktail: e.g., Ready‐Solv HP (Beckman Coulter)
Tissue homogenizer (e.g., T 25 Ultra‐Turrax; IKA Works)
Deep‐well 96‐well microtiter plates (2.2 ml volume; e.g., Bioblocks, Brandel), 2‐ml strip tubes, or 12×75–mm glass test tubes
GF/B Unifilter plates (Packard), or equivalent
Cell harvester or vacuum filtration manifold (e.g., Packard, Brandel, or Skatron), optional
60°C oven, optional

Additional reagents and equipment for preparing H₄ receptor membranes (see protocol 1 )

GO TO THE FULL PROTOCOL:

PDF or HTML at Wiley Online Library

Figures

Figure 1.19.1 Microtiter plate 96‐well format scheme for saturation binding assay providing 12 concentrations of radioligand covering a 100‐fold concentration range. Concentration 1 (0.09 nM in this example) is pipetted into row A, wells 1 through 6, to which have been added appropriate volumes of assay buffer for total binding wells and an appropriate concentration of a blocking agent for nonspecific binding (NSB) wells. This concentration of radioligand can also be pipetted into wells 1 and 2 of row G to serve as filter blanks, if desired. Similar steps are taken for each increasing concentration of radioligand (indicated by increased shading of the background) over a 100‐fold concentration range. The dilution strategy shown is suitable for [³ H]mepyramine binding to H₁ histaminergic receptors. There is a slight bias toward more concentrations of radioligand at the low end of the concentration range, because these are often more useful in defining the dissociation constant of the radioligand in subsequent data analyses. The signal‐to‐noise ratio is greater, and there is a more dynamic change in radioligand binding at these lower concentrations; these changes become less dynamic as saturation of receptor sites is approached. To explore additional concentrations of a well characterized radioligand with low filter blanks, rows G and H can be used for up to four more concentrations of radioligand. This dilution scheme was used in the assay illustrated in Figure

View Image

Figure 1.19.2 Microtiter plate 96‐well format scheme for competition binding assay, providing 11 concentrations for each of 4 test compounds. Compound 1 is pipetted into rows A and B, in concentrations ranging from 100 nM to 0.1 nM (final concentrations, allowing for dilution by addition of other reagents). Note that at each end of the concentration‐response curve, 10‐fold changes in the concentrations are used. This allows a broader coverage of concentration ranges, and it also places additional data points on those parts of a concentration‐response curve where greater dynamic changes in radioligand binding are anticipated. A compound expected or known to be more potent (Compound 2) is pipetted similarly into rows C and D, although 10‐fold lower concentrations are used than with compound 1. Rows E and F are filled with compound 3, which is expected to be very potent, such that concentrations in the picomolar range are used. Compound 4 is pipetted similarly to compound 1. Wells labeled “total” contain a corresponding volume of assay buffer or diluent for test compounds, and wells labeled “NSB” contain the same volume of the appropriate concentration of the compound used to define nonspecific binding.

View Image

Figure 1.19.3 Saturation binding results for H₁ receptors expressed in HEK‐293 cells, based on the assay illustrated in Figure . Human H₁ receptors were incubated with different concentrations of [³ H]mepyramine as described in . Nonspecific binding (triangles) was subtracted from total binding (circles) to yield specific binding (squares). As can be seen, most of the binding is specific. Transforming the specific binding data according to the procedure of Scatchard (inset) provides an estimate of the affinity of the radioligand ( K _d = 0.85 nM, derived from the inverse of the slope of the line) and the receptor density ( B _max = 2700 fmol/mg protein, derived from the x ‐intercept).

View Image

Figure 1.19.4 Saturation binding results for human H₂ receptors expressed in HEK‐293 cells, based on an assay strategy similar to that illustrated in Figure . Human H₂ receptors were incubated with different concentrations of [³ H]tiotidine as described in . Nonspecific binding (triangles) was subtracted from total binding (circles) to yield specific binding (squares). As can be seen, most of the binding is specific binding. Transforming the specific binding data according to the procedure of Scatchard (inset) provides an estimate of the affinity of the radioligand ( K _d = 6.6 nM) and the receptor density ( B _max = 23 pmol/mg protein).

View Image

Figure 1.19.5 Saturation binding results for human H₃ receptors expressed in HEK‐293 cell membrane homogenates, based on the assay illustrated in Figure . Human H₃ receptors were incubated with different concentrations of [³ H] N ‐α‐methyl histamine (NAMH) as described in . Nonspecific binding (triangles) was subtracted from total binding (circles) to yield specific binding (squares). As can be seen, most of the binding is specific binding. Transforming the specific binding data according to the procedure of Scatchard (inset) provides an estimate of the affinity of the radioligand ( K _d = 0.50 nM) and the receptor density ( B _max = 1220 fmol/mg protein).

View Image

Videos

Literature Cited

	Alves‐Rodrigues, A., Leurs, R., Wu, T.S., Prell, G.D., Foged, C., and Timmerman, H. 1996. [3H]Thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex. Br. J. Pharmacol. 118:2045‐2052.
	Arrang, J.M., Garbarg, M., and Schwartz, J.C. 1983. Autoinhibition of brain histamine release by a novel class (H3) of histamine receptor. Nature 302:832‐837.
	Bakker, R.A., Timmerman, H., and Leurs, R. Histamine receptors: Specific ligands, receptor biochemistry, and signal transduction. 2002. Clin. Allergy Immunol. 17:27‐64.
	Barger, G., and Dale, J.J. 1910. Chemical structure and sympathomimetic action of amines. J. Physiol. 41:19‐59.
	Black, J.W., Duncan, W.A.M., Durant, G.J., Ganellin, C.R., and Parsons, M.E. 1972. Definition and antagonism of histamine H2 receptors. Nature 236:385‐390.
	Brown, J.D., O'Shaughnessy, C.T., Kilpatrick, G.J., Scopes, D.I.C., Beswick, P., Clitherow, J.W., and Barnes, J.C. 1996. Characterization of the specific binding of the histamine H3 receptor antagonist radioligand [3H]GR168320. Eur. J. Pharmacol. 311:305‐310.
	Cheng, Y.C. and Prusoff, W.H. 1973. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099‐3108.
	Coge, F., Guenin, S.P., Audinot, V., Renouard‐Try, A., Beauverger, P., Macia, C., Ouvry, C., Nagel, N., Rique, H., Boutin, J.A., and Galizzi, J.P. 2001. Genomic organization and characterization of splice variants of the human histamine H3 receptor. Biochem. J. 355:279‐288.
	De Backer, M.D., Gommeren, W., Moereels, H., Nobels, G., Van Gompel, P., Leysen, J.E., and Luyten, W.H. 1993. Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem. Biophys. Res. Commun. 197:1601‐1608.
	de Esch, I.J., Thurmond, R.L., Jongejan, A., and Leurs, R. 2005. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol. Sci. 26:462‐469.
	Drutel, G., Peitsaro, N., Karlstedt, K., Wieland, K., Smit, M.J., Timmerman, H., Panula, P., and Leurs, R. 2001. Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol. Pharmacol. 59:1‐8.
	Du Buske, L.M. 1996. Clinical comparison of histamine H1‐receptor antagonist drugs. J. Allergy Clin. Immunol. 98:S307‐S318.
	Esbenshade, T.A., Fox, G.B., and Cowart, M.D. 2006. Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Mol. Interv. 6:77‐88.
	Fourneau, E. and Bovet, D. 1933. Recherches sur l'action sympathicolytique d'un nouveau dérivé du dioxane. Arch. Int. Pharmacodyn. 46:179‐191.
	Gantz, I., Munzert, G., Tashiro, T., Schaffer, M., Wang, L., DelValle, J., and Yamada, T. 1991. Molecular cloning of the human histamine H2 receptor. Biochem. Biophys. Res. Commun. 178:1386‐1392.
	Hancock, A.A., Esbenshade, T.A., Krueger, K.M., and Yao, B.B. 2003. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. J. Life Sci. 73:3043‐3072.
	Harper, E.A., Shankley, N.P., and Black, J.W. 1997. Characterisation of the binding of the histamine H3‐receptor antagonist, [3H]clobenpropit, to sites in guinea‐pig cerebral cortex membranes. Br. J. Pharmacol. 122:432P.
	Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., Schunack, W., Levi, R., and Haas, H.L. 1997. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 49:253‐278.
	Jansen, F.P., Rademaker, B., Bast, A., and Timmerman, H. 1992. The first radiolabeled histamine H3 receptor antagonist, [125I]iodophenpropit: Saturable and reversible binding to rat cortex membranes. Eur. J. Pharmacol. 217:203‐205.
	Leurs, R., Smit, M.J., and Timmerman, H. 1995. Molecular pharmacological aspects of histamine receptors. Pharmacol. Ther. 66:413‐463.
	Leurs, R., Bakker, R.A., Timmerman, H., and de Esch, I.J. 2005. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov. 4:107‐120.
	Ligneau, X., Garbarg, M., Vizuete, L., Diaz, J., Purand, K., Stark, H., Schunack, W., and Schwartz, J‐C. 1994. [125I]Iodoproxyfan, a new antagonist to label and visualize cerebral histamine H2 receptors. J. Pharmacol. Exp. Ther. 271:452‐459.
	Liu, C., Ma, X., Jiang, X., Wilson, S.J., Hofstra, C.L., Blevitt, J., Pyati, J., Li, X., Chai, W., Carruthers, N., and Lovenberg, T.W. 2001a. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59:420‐426.
	Liu, C., Wilson, S.J., Kuei, C., and Lovenberg, T.W. 2001b. Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 299:121‐130.
	Lovenberg, T.W., Roland, B.L., Wilson, S.J., Jiang, X., Pyati, J., Huvar, A., Jackson, M.R., and Erlander, M.G. 1999. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 55:1101‐1107.
	Lovenberg, T.W., Pyati, J., Chang, H., Wilson, S.J., and Erlander, M.G. 2000. Cloning of rat H3 receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Therap. 293:771‐778.
	Oda, T., Morikawa, N., Saito, Y., Masuho, Y., and Matsumoto, S.‐I. 2000. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 275:36781‐36786.
	Thurmond, R.L., Desai, P.J., Dunford, P.J., Fung‐Leung, W.‐P., Hofstra, C.L., Jiang, W., Nguyen, S., Riley, J.P., Sun, S., Williams, K.N., Edwards, J.P., and Karlsson, L. 2004. A potent and selective histamine H4 receptor sntagonist with snti‐Inflammatory properties. J. Pharmacol. Exp. Ther. 309:404‐413.
	West, R.E. Jr., Zwieg, A., Shih, N.Y., Siegel, M.I., Egan, R.W., and Clark, M.A. 1990. Identification of H3 histamine receptor subtypes. Mol. Pharmacol. 38:610‐613.
	West, R.E. Jr., Wu, R‐L., Billah, M.M., Egan, R.W., and Anthes, J.C. 1999. The profiles of human and primate [3H]Nα‐methyl histamine binding differ from that of rodents. Eur. J. Pharmacol. 177:233‐239.
	Witte, D.G., Yao, B.B., Miller, T.R., Carr, T.L., Cassar, S., Sharma, R., Faghih, R., Surber, B.W., Esbenshade, T.A., Hancock, A.A., and Krueger, K.M. 2006. Detection of multiple H3 receptor affinity states utilizing [3H]A‐349821, a novel, selective, non‐imidazole histamine H3 receptor inverse agonist radioligand. Br. J. Pharmacol. 148:657‐670.
	Yao, B.B., Witte, D.G., Miller, T.R., Carr, T.L., Kang, C.H., Cassar, S., Faghih, R., Bennani, Y.L., Surber, B.W., Hancock, A.A., and Esbenshade, T.A. 2006. Use of an inverse agonist radioligand [3H]A‐317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor. Neuropharmacology. 50:468‐478.
Key References
	De Backer, et al., 1993. See above.
	Cloning of the human H1 receptor gene and initial pharmacological characterization.
	Gantz et al., 1991. See above.
	Cloning of the human H2 receptor gene and initial pharmacological characterization.
	Gajtkowski, G.A., Norris, D.B., Rising, T.J., and Wood, T.P. 1983. Specific binding of [3H]tiotidine to histamine H2 receptors in guinea‐pig cerebral cortex. Nature 304:65‐67.
	First successful radioligand described for H2 receptors after a number of false starts.
	Hancock et al., 2003. See above.
	Comprehensive review of histamine H3 receptor isoform heterogeneity.
	Lovenberg et al., 1999. See above.
	Cloning of the human H3 receptor gene and initial pharmacological characterization.
	Oda et al., 2000. See above.
	Cloning of the human H4 receptor gene and initial pharmacological characterization.
	West et al., 1999. See above.
	Characterization of homogenate radioligand binding in rat, human and non‐human primate brain indicating pharmacological differences may exist.

GO TO THE FULL PROTOCOL:

PDF or HTML at Wiley Online Library

关于丁香通

公司信息

个人用户

企业机构

无忧采购轻松科研

提问

扫一扫

实验小助手

扫码领资料

反馈

TOP

打开小程序

Characterization of Histaminergic Receptors

Abstract

Table of Contents

Materials

Basic Protocol 1: Measurement of [3H]Mepyramine Binding to Cloned Human H1 Receptors

Alternate Protocol 1: Measurement of [3H]mepyramine Binding to Native H1 Receptors in Tissue Membrane Homogenates

Basic Protocol 2: Measurement Of [3H]tiotidine Binding to Cloned Human H2 Receptors

Alternate Protocol 2: Measurement of [125I]aminopotentidine Binding to Native H2 Receptors in Tissue Membrane Homogenates

Basic Protocol 3: Measurement of [3H]N‐α‐Methyl Histamine Binding to Cloned Human H3 Receptors in Membranes

Alternate Protocol 3: Measurement of [3H]N‐α‐Methyl Histamine Binding to Native H3 Receptors

Basic Protocol 4: Measurement of [3H]histamine Binding to Cloned Human H4 Receptors in Membranes

Figures

Videos

Literature Cited

关于丁香通

公司信息

个人用户

企业机构